Joe Rogan recently praised BPC-157 during an episode of The Joe Rogan Experience with Andrew Schulz, calling it a key component of the “Wolverine” peptide stack for recovery and healing.
The podcast host claimed the peptide is effective enough that organizations like USADA have banned it because it accelerates recovery. He said, “Let me tell you something, there’s a reason why USADA didn’t let people use it in the UFC and now d**g-free sport also doesn’t let people use it in the UFC it’s because it works.”
But here’s the twist: despite being added to the WADA prohibited list in 2022, not a single athlete has failed a test for it.
BPC-157 is a 15 amino acid peptide derived from a protein found in human gastric juice. It has become something of an underground phenomenon in athletic and fitness circles. The compound has accumulated hundreds of thousands of positive reports, mostly regarding connective tissue healing.
Bodybuilders, Olympic weightlifters, CrossFit athletes, and general fitness enthusiasts have all turned to BPC-157 for tendon and ligament injuries.
Despite its popularity, the peptide remains in a regulatory gray area. There’s only one abandoned human clinical trial and approximately 180 studies, the vast majority performed on animal models, primarily rats.
The lack of human safety data hasn’t stopped widespread use, however, with anecdotal evidence suggesting the compound is generally well tolerated when administered at typical dosages of 200 to 1,000 micrograms.
The only documented case involving BPC-157 and competitive sports is UFC flyweight Courtney Casey, who received a four-month ban in June 2023 after self-reporting her use of the peptide. No athlete has actually failed a test for BPC-157, despite testing methods being available since it was added to WADA’s prohibited list.
Research on detection windows remains limited. Studies show that BPC-157 remains detectable in human urine for at least four days when added directly, while animal studies suggest at least three days following intramuscular administration. The actual detection window in humans following typical administration protocols remains unknown.
In September 2023, the FDA further complicated matters by limiting how US-based compounding pharmacies can prescribe BPC-157 under Section 503a, citing insufficient safety information. The irony is that while the FDA claims limited safety data exists, one human study from 2021 showed 87.5% of patients experienced improvement in knee pain following treatment with BPC-157 alone or combined with thymosin beta-4.
The peptide works through multiple mechanisms, including promoting blood vessel growth, modulating blood pressure, supporting immune function, and improving collagen synthesis.
Research suggests it may increase growth hormone receptor expression in tendon tissue, making it particularly effective when combined with growth hormone for injury recovery.
Rogan stated during the podcast: “The idea is that it’s performance enhancing because it lets you heal quicker. So heal from injuries quicker potentially heal from recovering, from training quicker.”
For now, BPC-157 occupies a unique position: banned by international sports organizations, restricted by the FDA, yet completely undetectable in actual competitive testing.
